Jim Cramer's Clover Health Pick Highlights Speculative Healthcare Risk
3h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
jim-cramerclover-health
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Market commentator Jim Cramer characterized Clover Health as a good speculative pick in a recent analysis, while maintaining a clear preference for established giants UnitedHealth Group and CVS Health. The commentary, reported by finance.yahoo.com on June 20, 2026, underscores a persistent divide within the healthcare sector between mature, cash-rich insurers and younger, technology-focused firms navigating a volatile regulatory landscape. Cramer's distinction highlights a core investment thesis: scale and diversification remain paramount in the current economic environment characterized by rising interest rates and persistent inflation pressures.
Cramer's commentary arrives amid heightened scrutiny of Medicare Advantage plans and the financial viability of newer market entrants. The last major regulatory pivot affecting this space occurred in April 2023, when the Centers for Medicare & Medicaid Services finalized a 1.1% average rate cut for 2024, triggering a sector-wide sell-off that erased over $40 billion in market value from top insurers in a single session. That precedent established a sensitivity to policy shifts that continues to define investment flows.
The current macro backdrop features the Federal Reserve's policy rate anchored above 5%, raising the cost of capital for all firms but disproportionately pressuring those without consistent free cash flow. The 10-year Treasury yield sits at 4.31%, a level that compresses valuation multiples for long-duration growth assets. What triggered this specific commentary now is the approaching annual rate announcement cycle for Medicare Advantage, a key revenue driver for both Clover and its larger peers, coupled with recent earnings volatility among smaller, tech-enabled health plans.
The financial chasm between Cramer's favored picks and the speculative segment is stark. UnitedHealth Group commands a market capitalization exceeding $480 billion, while Clover Health's valuation is approximately $600 million. UnitedHealth's trailing twelve-month operating margin is 8.7%, compared to Clover Health's reported operating loss. Over the past year, the Health Care Select Sector SPDR Fund (XLV) has returned 5.2%, significantly underperforming the S&P 500's 12.8% gain.
| Metric | UnitedHealth Group (UNH) | Clover Health (CLOV) |
|---|---|---|
| Market Cap | $481 billion | $0.6 billion |
| 1-Year Return | +4.1% | -18.5% |
| Revenue (TTM) | $371.6 billion | $1.3 billion |
| P/E Ratio (TTM) | 24.3 | N/A (negative earnings) |
This performance divergence extends to credit metrics. UnitedHealth maintains an A+ credit rating from S&P Global, while Clover Health operates without a public corporate credit rating. The iShares U.S. Healthcare Providers ETF (IHF), heavily weighted toward insurers, shows a 30-day volatility measure of 14%, whereas the Defiance Digital Health ETF (ARKG), focused on innovation, exhibits volatility above 28%.
The second-order effects of capital favoring scaled operators are clear. Companies like CVS Health and Elevance Health benefit from their integrated pharmacy and insurance models, which generate stable cash flows to fund dividends and buybacks. Analysts project these firms could see incremental capital inflows from investors rotating out of speculative healthcare tech, potentially supporting share prices even in a broader market downturn. Conversely, smaller Medicare Advantage-focused plans like Alignment Healthcare and Cano Health face heightened pressure on their cost structures and access to funding.
A key limitation to this thesis is the potential for disruptive innovation. A successful rollout of a proprietary, cost-saving technology platform by a firm like Clover could rapidly alter its unit economics and investor perception, though such an outcome is not currently priced in. Positioning data from the latest CFTC Commitment of Traders report shows asset managers maintaining a net long position in healthcare, but with a pronounced skew toward the pharmaceutical and managed care sub-sectors, not healthcare services or technology.
The primary immediate catalyst is the Q2 2026 earnings season, commencing in mid-July. Investors will scrutinize Clover Health's medical cost ratio and membership growth, while focusing on UnitedHealth and CVS's guidance for 2027. A key level to watch for Clover Health is the $1.20 share price, a technical support level that, if broken, could trigger further selling. For UnitedHealth, the $520 level represents a multi-month resistance zone; a sustained breakout could signal renewed institutional confidence.
The next Federal Open Market Committee decision on July 30 will also impact sector valuations. Any signal of a prolonged higher-rate environment will continue to disadvantage pre-profit companies. Finally, the draft 2028 Medicare Advantage rate notice, expected in early February 2027, will set the tone for the next full year. Markets will parse the proposal for any changes to risk adjustment models or benchmark rates that could disproportionately affect smaller insurers.
For retail investors, Cramer's distinction underscores the importance of understanding a company's fundamental financial runway. Speculative picks like Clover Health are high-risk assets suitable only for a small, discretionary portion of a portfolio, as they are highly sensitive to funding costs and regulatory news. Established giants like UnitedHealth offer relative stability and income via dividends, aligning with a core holding strategy. The commentary serves as a reminder to align individual stock risk with overall portfolio construction and risk tolerance.
Clover Health operates primarily as a Medicare Advantage insurer with a focus on its proprietary Clover Assistant software platform, which aims to provide physicians with data analytics for improved patient care. Its model is concentrated and technology-driven. UnitedHealth Group has a vast, diversified model spanning UnitedHealthcare (insurance) and Optum (health services, technology, and pharmacy benefit management). This diversification across insurance, care delivery, and data analytics provides multiple revenue streams and significant economies of scale, insulating it from shocks in any single business line.
Historically, during periods of rising interest rates and economic uncertainty, large-cap, profitable healthcare stocks have significantly outperformed their speculative peers. Following the 2023 Medicare Advantage rate announcement, the NYSE Arca Pharmaceutical Index (DRG) fell 3% over the next month, while the SPDR S&P Biotech ETF (XBI) plummeted over 15%. This pattern repeated during the 2015-2018 Fed hiking cycle, where the XLV ETF gained 32% while a basket of pre-revenue healthcare tech stocks declined by an average of 22%. The performance gap typically narrows during periods of easy monetary policy and strong risk appetite.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.